Frank X. Leonard

Insider Reports History

Location
Malvern, PA
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Frank X. Leonard:

Company Role Class Num Shares Value Price $ Report Date Ownership
NovoCure Ltd Chief Executive Officer Ordinary Shares 349,400 $4,714,454 $13.49 02 Mar 2026 Direct
NovoCure Ltd Chief Executive Officer Stock Options (Right to buy) 81,499 $1,482,467 $18.19 04 Mar 2025 Direct

Insider Reports Filed by Frank X. Leonard

Symbol Company Period Transactions Value $ Form Type Role Filing Time
NVCR NovoCure Ltd 27 Feb 2026 3 -$230,585 4 Chief Executive Officer 03 Mar 2026, 16:09
NVCR NovoCure Ltd 01 Nov 2025 1 -$12,374 4 EVP, Pres., Novocure Oncology 04 Nov 2025, 16:09
NVCR NovoCure Ltd 30 Jun 2025 1 +$12,603 4 EVP, Pres., Novocure Oncology 01 Jul 2025, 16:19
NVCR NovoCure Ltd 04 Jun 2025 1 $0 4 EVP, Pres., Novocure Oncology 06 Jun 2025, 16:10
NVCR NovoCure Ltd 02 Jun 2025 3 -$528,413 4 EVP, Pres., Novocure Oncology 04 Jun 2025, 16:09
NVCR NovoCure Ltd 04 Mar 2025 2 +$2,482,462 4 EVP, Pres., Novocure Oncology 06 Mar 2025, 16:41
NVCR NovoCure Ltd 03 Mar 2025 1 -$46,841 4 EVP, Pres., Novocure Oncology 04 Mar 2025, 16:19
NVCR NovoCure Ltd 27 Feb 2025 3 -$296,257 4/A EVP, Pres., Novocure Oncology 03 Mar 2025, 21:26
NVCR NovoCure Ltd 01 Nov 2024 1 -$9,531 4 EVP, Pres., Novocure Oncology 04 Nov 2024, 16:34
NVCR NovoCure Ltd 28 Jun 2024 1 +$21,249 4 EVP, Pres., Novocure Oncology 06 Aug 2024, 16:17
NVCR NovoCure Ltd 01 Mar 2024 2 -$40,358 4 EVP, Pres., Novocure Oncology 05 Mar 2024, 16:08
NVCR NovoCure Ltd 27 Feb 2024 3 +$4,181,586 4 EVP, Pres., Novocure Oncology 29 Feb 2024, 16:38
NVCR NovoCure Ltd 04 Jan 2024 0 $0 3 EVP, Pres., Novocure Oncology 12 Jan 2024, 16:57
NVCR NovoCure Ltd 03 Mar 2023 4 -$1,028,165 4 President, CNS Cancers US 07 Mar 2023, 15:52
NVCR NovoCure Ltd 02 Mar 2023 3 -$223,393 4 President, CNS Cancers US 06 Mar 2023, 15:37
NVCR NovoCure Ltd 02 Mar 2023 2 -$309,578 4 President, CNS Cancers US 03 Mar 2023, 15:13
NVCR NovoCure Ltd 28 Feb 2023 3 +$2,255,244 4 President, CNS Cancers US 02 Mar 2023, 16:01
NVCR NovoCure Ltd 05 Jan 2023 19 -$3,892,957 4 President, CNS Cancers US 09 Jan 2023, 17:21
NVCR NovoCure Ltd 01 Nov 2022 2 +$849,779 4 President, CNS Cancers US 03 Nov 2022, 16:42
NVCR NovoCure Ltd 13 Oct 2022 1 -$513,372 4 President, CNS Cancers US 17 Oct 2022, 16:35
NVCR NovoCure Ltd 06 Oct 2022 1 -$569,835 4 President, CNS Cancers US 07 Oct 2022, 16:16
NVCR NovoCure Ltd 29 Sep 2022 1 -$522,422 4 President, CNS Cancers US 30 Sep 2022, 16:20
NVCR NovoCure Ltd 22 Sep 2022 1 -$520,058 4 President, CNS Cancers US 26 Sep 2022, 16:19
NVCR NovoCure Ltd 15 Sep 2022 4 -$1,046,775 4 Chief Development Officer 19 Sep 2022, 16:10
NVCR NovoCure Ltd 09 Sep 2022 1 -$163,944 4 Chief Development Officer 12 Sep 2022, 16:32
NVCR NovoCure Ltd 08 Sep 2022 1 -$550,316 4/A Chief Development Officer 13 Sep 2022, 16:15
NVCR NovoCure Ltd 06 Sep 2022 1 -$108,741 4 Chief Development Officer 07 Sep 2022, 16:27
NVCR NovoCure Ltd 01 Sep 2022 13 -$1,146,634 4 Chief Development Officer 06 Sep 2022, 16:19
NVCR NovoCure Ltd 02 Aug 2022 1 -$28,839 4 Chief Development Officer 03 Aug 2022, 16:44
NVCR NovoCure Ltd 05 Jul 2022 1 +$18,431 4 Chief Development Officer 07 Jul 2022, 17:46
NVCR NovoCure Ltd 08 Mar 2022 1 -$52,154 4 Chief Development Officer 09 Mar 2022, 15:55
NVCR NovoCure Ltd 03 Mar 2022 5 +$2,740,900 4 Chief Development Officer 07 Mar 2022, 17:14
NVCR NovoCure Ltd 02 Sep 2021 1 -$74,645 4 Chief Development Officer 07 Sep 2021, 16:39
NVCR NovoCure Ltd 02 Aug 2021 2 -$155,520 4 Chief Development Officer 04 Aug 2021, 17:20
NVCR NovoCure Ltd 06 Jul 2021 1 +$21,117 4 Chief Development Officer 08 Jul 2021, 17:36